Carfilzomib treatment associated with cardiovascular events in myeloma patients

A meta-analysis conducted by researchers at the University of Pennsylvania has shown that treatment with carfilzomib (Kyprolis┬«) is associated with a higher incidence of cardiovascular events in myeloma patients. The study found that 18.1% of myeloma patients receiving carfilzomib experienced cardiovascular events, including hypertension, cardiac arrest, cardiac failure and arrhythmias, compared to only 3.8% of…

Details